DE60020352D1 - Zusammensetzung und methode zur induzierung von apoptosis in prostatakrebszellen mittels m-dna und mcc - Google Patents

Zusammensetzung und methode zur induzierung von apoptosis in prostatakrebszellen mittels m-dna und mcc

Info

Publication number
DE60020352D1
DE60020352D1 DE60020352T DE60020352T DE60020352D1 DE 60020352 D1 DE60020352 D1 DE 60020352D1 DE 60020352 T DE60020352 T DE 60020352T DE 60020352 T DE60020352 T DE 60020352T DE 60020352 D1 DE60020352 D1 DE 60020352D1
Authority
DE
Germany
Prior art keywords
dna
prostate
mcc
composition
apoptosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60020352T
Other languages
English (en)
Other versions
DE60020352T2 (de
Inventor
C Phillips
C Filion
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Telesta Therapeutics Inc
Original Assignee
Bioniche Life Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioniche Life Sciences Inc filed Critical Bioniche Life Sciences Inc
Publication of DE60020352D1 publication Critical patent/DE60020352D1/de
Application granted granted Critical
Publication of DE60020352T2 publication Critical patent/DE60020352T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60020352T 1999-04-01 2000-03-30 Zusammensetzung und Methode zur Inuzierung von Apptosis in Prostatakrebszellen mittels M-DNA und MCC Expired - Lifetime DE60020352T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12745199P 1999-04-01 1999-04-01
US127451P 1999-04-01
PCT/CA2000/000342 WO2000059518A2 (en) 1999-04-01 2000-03-30 Composition and method for inducing apoptosis in prostate cancer cells

Publications (2)

Publication Number Publication Date
DE60020352D1 true DE60020352D1 (de) 2005-06-30
DE60020352T2 DE60020352T2 (de) 2005-10-20

Family

ID=22430191

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60020352T Expired - Lifetime DE60020352T2 (de) 1999-04-01 2000-03-30 Zusammensetzung und Methode zur Inuzierung von Apptosis in Prostatakrebszellen mittels M-DNA und MCC

Country Status (10)

Country Link
EP (1) EP1165106B8 (de)
JP (1) JP2002541114A (de)
AT (1) ATE296106T1 (de)
AU (1) AU780909B2 (de)
CA (1) CA2366090C (de)
CY (1) CY1107455T1 (de)
DE (1) DE60020352T2 (de)
ES (1) ES2238996T3 (de)
PT (1) PT1165106E (de)
WO (1) WO2000059518A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2354047C (en) * 1998-12-04 2007-08-14 Bioniche Life Sciences Inc. Method for the treatment of inflammation
US20030044352A1 (en) * 2001-04-24 2003-03-06 Phillips Nigel C. Method for evaluating the efficacy of treatment with bacterial DNA and bacterial cell walls

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4335435B2 (ja) * 1997-08-05 2009-09-30 バイオニケ ライフ サイエンシーズ インコーポレイテッド 細胞増殖および細胞死を調節する組成物および方法

Also Published As

Publication number Publication date
EP1165106B1 (de) 2005-05-25
EP1165106B8 (de) 2005-07-27
WO2000059518A2 (en) 2000-10-12
CY1107455T1 (el) 2012-12-19
AU3413500A (en) 2000-10-23
WO2000059518A3 (en) 2001-02-01
JP2002541114A (ja) 2002-12-03
EP1165106A2 (de) 2002-01-02
DE60020352T2 (de) 2005-10-20
CA2366090A1 (en) 2000-10-12
ATE296106T1 (de) 2005-06-15
ES2238996T3 (es) 2005-09-16
CA2366090C (en) 2011-05-24
AU780909B2 (en) 2005-04-21
PT1165106E (pt) 2005-10-31

Similar Documents

Publication Publication Date Title
MY121548A (en) Compounds and methods for the treatment of cancer
BR9709015A (pt) Quinolina carboxamidas como inbidores de tnf e como inbidores de pde-iv
EA200600424A1 (ru) Применение полипептидов семейства купредоксинов при лечении рака
DK1280552T3 (da) Fremgangsmåde til behandling af hudcancer ved anvendelse af præparater der omfatter en endothelin B-receptor-inhibitor
ATE296839T1 (de) Antikörper zur krebsbehandlung und -diagnose
ID26620A (id) Penghambatan kinase raf yang menggunakan urea-urea heterosiklik yang disubstitusi
DE60027719D1 (de) Krebstherapie
DE60027768D1 (de) Behandlung von metastatischer krankheit
TW200728465A (en) Compositions and methods for the therapy and diagnosis of prostate cancer
ATE488529T1 (de) Zusammensetzungen und verfahren zur behandlung von tumoren
EA200300934A1 (ru) Агенты и способы, предназначенные для лечения опухолевых заболеваний
WO2004009112A8 (en) Use of urease for inhibiting cancer cell growth
DE60044350D1 (de) Prostata-spezifisches gen pcgem1 und methoden zu dessen verwendung zur erkennung, behandlung und prävention von prostatakrebs
ATE287722T1 (de) Mittel zur behandlung maligner erkrankungen unter verwendung des proteins yb-1
DE69533873D1 (de) Krebstherapie mit lymphotoxin
DE60020352D1 (de) Zusammensetzung und methode zur induzierung von apoptosis in prostatakrebszellen mittels m-dna und mcc
ATE243522T1 (de) Verwendung von tall-104 zellen in kombination mit adriamyzin oder cisplatin zur behandlung von malignen tumoren
DK0768886T3 (da) Endothelforingseffekter og behandling af vasospastiske lidelser
WO2004013313A3 (en) Antisense nucleic acids
EA200601630A1 (ru) Ниосома, имеющая внедрённый в неё маталлопорфириновый комплекс, способ её получения и лекарственное средство с её использованием
DK0579791T3 (da) Cellulær sammensætning til behandling af menneske- og dyreorganismer
DK1054680T3 (da) Behandling af blærecancer med mycobacterium phlei cellevæg
MXPA05009715A (es) Anticuerpo contra antigeno especifico de tumor como objetivo.
ATE537838T1 (de) Kombinationstherapie mit kloretazin(tm)
DE69734690D1 (de) Monoklonaler Antikörper gegen Fibroblasten-Wachstumsfaktor-8

Legal Events

Date Code Title Description
8381 Inventor (new situation)

Inventor name: READER, STEPHANIE, QUEBEC, CA

Inventor name: FILION, C., MARIO, MONTREAL, CA

Inventor name: PHILLIPS, C., NIGEL, POINT-CLAIRE, CA

8364 No opposition during term of opposition